Clinical case reports and animal studies that were presented support the broad potential of AC5 Advanced Wound System in a range of complicated acute and chronic wounds FRAMINGHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and… Read More..

SOUTH ORANGE, NJ, Nov. 09, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will participate at the following investor conferences in November.… Read More..

Clinical and pre-clinical data continues to support potential of KZR-616 to positively effect multiple drivers of immune-mediated diseases Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted the broad therapeutic potential of KZR-616, a first-in-class immunoproteasome inhibitor,… Read More..